MedTrace Logo

A Translational Study of Tumor Antigen-pulsed DC Vaccine for ESCC

NCT05317325 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2022-04-07

No results posted yet for this study

Summary

The aim of this single center, single arm and prospective study is to explore the safety and efficacy of tumor antigen-pulsed DC vaccine( OCDC and NeoDC) for postoperative adjuvant treatment of ESCC

Conditions

Interventions

BIOLOGICAL

OCDC vaccine; NeoDC vaccine

OCDC vaccine and NeoDC vaccine are administered in a prime-boost regimen by subcutaneous injection.

Sponsors & Collaborators

  • Sichuan University

    lead OTHER

Principal Investigators

  • Zhen-Yu Ding, Prof · Sichuan University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-01
Primary Completion
2023-12-30
Completion
2024-04-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05317325 on ClinicalTrials.gov